Blincyto by Amgen is a medicine used to treat a blood cancer called B-precursor acute lymphoblastic leukaemia (ALL) in patients above 1 year of age when the cancer has come back or has not improved with previous treatment.
Blincyto is used for patients who are ‘Philadelphia-chromosome-negative’ which means that the patients do not have an abnormal chromosome called the Philadelphia chromosome, and in patients who have the protein CD19 on their white blood cells (CD19-positive).